Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Oxygen-Enhanced MRI could sharpen radiotherapy for deadly brain cancers

NCT ID NCT07670455

Diagnosis Sponsor: The Leeds Teaching Hospitals NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study tests whether oxygen-enhanced MRI (OE-MRI) can identify low-oxygen (hypoxic) regions in high-grade gliomas, the most common and aggressive adult brain cancers. Twenty-five patients will undergo OE-MRI scans before, during, and after standard radiotherapy. Researchers will then use computer models to see if targeting those hypoxic areas with higher radiation doses could improve tumor control. The study does not change actual treatment—it is purely imaging and planning.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Oxygen-enhanced MRI (OE-MRI)
What this could lead to
If successful, this imaging technique could help doctors target radiotherapy more precisely to low-oxygen tumor areas, potentially improving treatment for aggressive brain cancers.
What could go wrong
This is a small, early-stage imaging study (25 participants) that only models higher radiation doses—it does not test actual treatment changes. The technique may not reliably detect hypoxia or improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥18yrs. * Participants able to communicate with staff and safely comply with the study procedures. * Participants to provide informed written consent. Exclusion Criteria: * Participants with any MRI contraindications including inability to lie flat in MRI scanner, claustrophobia and no foreign bodies, medical devices or other items which are considered an MRI contraindication. * Geographically remote patients unable to agree to imaging schedule. * Participants with illness or condition which means they cannot understand the requirements of the study. * Participants with cardiac or pulmonary disease that are unable to tolerate the flow of oxygen delivered via a mask. * Participants who have previously been treated with bleomycin (a chemotherapy used to treat some cancers including Hodgkin lymphoma and germ cell tumours). * Participants with contraindications to gadolinium-based contrast agent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain neoplasms, adult are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer brain hypoxia - ischemia brain neoplasm glioblastoma Hypoxia, Brain malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain neoplasms, adult Glioblastoma (GBM) High grade gliomas Hypoxia, brain

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.